无码欧美成人av天堂456软件,大胆日本熟妇XXXX,9277在线观看免费播放,4p三个男人让我爽了一夜

產(chǎn)品訂購信息：
英文名稱  Anti-Phospho-Tie2 (Ser1119) 

中文名稱   磷酸化生成素受體2抗體品牌 

別    名  Tie-2; Tie2; Tek; Angiopoietin-1 receptor; Tyrosine-protein kinase receptor TIE-2; hTIE2; Tyrosine-protein kinase receptor TEK; Tunica interna endothelial cell kinase; p140 TEK; Angiopoietin 1 receptor; CD202b; CD202b antigen; Endothelial tyrosine kinase; Endothelium specific receptor tyrosine kinase 2; hTIE 2; Hyk; Soluble TIE2 variant 1; Soluble TIE2 variant 2; tek tyrosine kinase; TEK tyrosine kinase endothelial; tek tyrosine kinase, endothelial; TIE 2; TIE2_HUMAN; Tunica interna endothelial cell kinase; Tyrosine kinase with Ig and EGF homology domains 2; Tyrosine protein kinase receptor TEK; Tyrosine protein kinase receptor TIE 2; Tyrosine-protein kinase receptor TIE-2; Venous malformations multiple cutaneous and mucosal; VMCM 1; VMCM; VMCM1; CD202b.

濃    度   1mg/1ml

規(guī) 格  0.1ml/100μg

抗體來源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep 

產(chǎn)品類型   一抗 磷酸化抗體  

研究領(lǐng)域     心 信號轉(zhuǎn)導(dǎo) 干細胞 生長因子和激素 激酶和磷酸酶

蛋白分子量  predicted molecular weight: 124kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human Tie2 around the phosphorylation site of Ser1119 

亞    型   IgG

純化方法   affinity purified by Protein A

儲 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

磷酸化生成素受體2抗體品牌 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 The TEK receptor tyrosine kinase is expressed almost exclusively in endothelial cells in mice, rats, and humans. This receptor possesses a unique extracellular domain containing 2 immunoglobulin-like loops separated by 3 epidermal growth factor-like repeats that are connected to 3 fibronectin type III-like repeats. The ligand for the receptor is angiopoietin-1. Defects in TEK are associated with inherited venous malformations; the TEK signaling pathway appears to be critical for endothelial cell-smooth muscle cell communication in venous morphogenesis.TEK is closely related to the TIE receptor tyrosine kinase.

Function : Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.

Subunit : Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.

Subcellular Location : Cell membrane; Single-pass type I membrane protein. Cell junction. Cell junction, focal adhesion. Cytoplasm, cytoskeleton. Secreted.

Tissue Specificity : Detected in umbilical vein endothelial cells. Proteolytic processing gives rise to a soluble extracellular domain that is detected in blood plasma (at protein level). Predominantly expressed in endothelial cells and their progenitors, the angioblasts. Has been directly found in placenta and lung, with a lower level in umbilical vein endothelial cells, brain and kidney.

Post-translational modifications : Proteolytic processing leads to the shedding of the extracellular domain (soluble TIE-2 alias sTIE-2).

Autophosphorylated on tyrosine residues in response to ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Autophosphorylation occurs in a sequential manner, where Tyr-992 in the kinase activation loop is phosphorylated first, followed by autophosphorylation at Tyr-1108 and at additional tyrosine residues. ANGPT1-induced phosphorylation is impaired during hypoxia, due to increased expression of ANGPT2. Phosphorylation is important for interaction with GRB14, PIK3R1 and PTPN11. Phosphorylation at Tyr-1102 is important for interaction with SHC1, GRB2 and GRB7. Phosphorylation at Tyr-1108 is important for interaction with DOK2 and for coupling to downstream signal transduction pathways in endothelial cells. Dephosphorylated by PTPRB.

Ubiquitinated. The phosphorylated receptor is ubiquitinated and internalized, leading to its degradation.

DISEASE : Defects in TEK are a cause of dominantly inherited venous malformations (VMCM) [MIM:600195]; an error of vascular morphogenesis characterized by dilated, serpiginous channels.

Note=May play a role in a range of diseases with a vascular component, including neovascularization of tumors, psoriasis and inflammation.

Similarity : Belongs to the protein kinase superfamily. Tyr protein kinase family. Tie subfamily.

Contains 3 EGF-like domains.

Contains 3 fibronectin type-III domains.

Contains 2 Ig-like C2-type (immunoglobulin-like)domains.

Contains 1 protein kinase domain.

Database links : UniProtKB/Swiss-Prot: Q02763.2

Tie2 是內(nèi)皮特異性的酪氨酸激酶型受體, 主要表達在肺內(nèi)皮以及卵泡、創(chuàng)口肉芽組織等內(nèi)皮. 在發(fā)育中起重要的.

EPO human 人促紅細胞生成素Multi-class antibodies

Anti-c-Myc tag c-Myc tag標簽抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh NPAP1 核孔蛋白1抗體 規(guī)格 0.2ml

CD3/FITC + CD56/PE FITC標記CD3抗體 + PE標記CD56抗體 0.1mlx2

TSKS 英文名稱： 特異激酶底物蛋白抗體 0.2ml

C6orf211 英文名稱： 6號染色體開放閱讀框211抗體 0.2ml

Anti-c-Myc tag c-Myc tag標簽抗體Multi-class antibodies規(guī)格： 0.1ml

NGX6 (nasopharyngeal carcinoma/NPC associated gene 6) 細胞相關(guān)基因6(多肽)Multi-class antibodies規(guī)格： 0.5mg

Anti-APOJ 載脂蛋白J抗體Multi-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh Phospho-ATRIP (Ser224) 先關(guān)蛋白TREX1抗體 規(guī)格 0.1ml

兔抗山羊 IgG(H+L)/AP 0.1ml 美國Jackson公司分裝

VEGF 英文名稱： 內(nèi)皮生長因子抗體 0.1ml

Desmoplakin I+II 英文名稱： 橋粒斑蛋白1+2抗體 0.1ml

Anti-APOJ 載脂蛋白J抗體Multi-class antibodies規(guī)格： 0.2ml

Anti-SSEA4/FITC 熒光素標記階段特異性胚胎表面抗原-4IgGMulti-class antibodies規(guī)格： 0.2ml

AMACR/P504S(alpha-methylacyl-CoA racemase) α-甲基酰基輔酶A消旋酶抗原Multi-class antibodies規(guī)格： 0.5mg

血小板源性生長因子受體-B抗體 Anti-PDGF-R-B 0.1ml

Secretogranin V 英文名稱： 神經(jīng)顆粒蛋白5抗體 0.2ml

ERAS 英文名稱： 胚胎干細胞RAS蛋白抗體 0.2ml

Rhesus antibody Rh phospho-NDEL1(Ser242) 磷酸化中心粒蛋白Nudel抗體 規(guī)格 0.1ml

AMACR/P504S(alpha-methylacyl-CoA racemase) α-甲基?；o酶A消旋酶抗原Multi-class antibodies規(guī)格： 0.5mg

大鼠免疫球蛋白G(IgG)ELISA 試劑盒 96T/48T 試劑盒 組裝/原裝

人生長調(diào)節(jié)致癌基因α/黑素瘤生長刺激因子(GROα/CXCL1/MGSA)免疫試劑盒 Human GROα/MGSA ELISA Kit

Mouseglucocoicoidreceptor,GRELISAKit小鼠糖皮質(zhì)類固醇受體(GR)ELISA試劑盒規(guī)格：96T/48T

Sophorajaponicaagglinin,SJAELISA試劑盒槐凝集素(SJA)ELISA試劑盒規(guī)格：96T/48T

HumanMaixmetalloproteinase10,MMP-10ELISA試劑盒人基質(zhì)金屬蛋白酶10(MMP-10)ELISA試劑盒規(guī)格：96T/48T

Humanphospholamban,PLNELISAKit人受磷蛋白(PLN)ELISA試劑盒規(guī)格：96T/48T

大鼠不對稱二甲基精酸(ADMA)ELISA試劑盒 96T/48T 試劑盒 組裝/原裝

人免疫球蛋白E Fc段受體Ⅰ(FcεRⅠ)免疫試劑盒 Human Receptor Ⅰ for the Fc region of immunoglobulin E,FcεRⅠ ELISA Kit

MouseVascuoarendothelialcellgrowthfactorreceptor1,VEGFR-1/Flt1ELISAKit小鼠內(nèi)皮細胞生長因子受體1(VEGFR-1/Flt1)ELISA試劑盒規(guī)格：96T/48T

石蠟切片組織CASPASE-3蛋白表達NBT顯色光學(xué)顯微鏡檢測試劑盒10/20次

humanProstaglandinF,PG-FELISA試劑盒人素F(PGF)ELISA試劑盒規(guī)格：96T/48T

HumahymosinELISAKit人胸腺肽(Thymosin)ELISA試劑盒規(guī)格：96T/48T

磷酸化生成素受體2抗體品牌 大鼠低氧誘導(dǎo)因子1α(HIF1α)ELISA試劑盒 ，英文名： HIF1α ELISA Kit

E selectin (E-Selectin/CD62E) ELISA Kit 人E選擇素(E-Selectin/CD62E)ELISA試劑盒

Ratmonocytechemotacticprotein3,MCP-3ELISAkit 大鼠單核細胞趨化蛋白3(MCP-3/CCL7)ELISA試劑盒 96T/48T 進口分裝

CLIAKitforCyPB(HumancyclophilinB)ELISAKit人嗜環(huán)蛋白/親環(huán)素B規(guī)格：48T/96T

細胞色素P450亞酶CYP2A(COD)活性熒光定量檢測試劑盒20次

Ratfreechorionicgonadoopin,f-βCGELISAKit大鼠游離β絨毛膜激素(f-βCG)ELISA試劑盒規(guī)格：96T/48T

抗體的生物素化標記實驗要點：

1. 磷酸化生成素受體2抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；

3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；

8.在細胞的熒光標記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細胞可導(dǎo)致高本底。

抗體的鑒定：

1）磷酸化生成素受體2抗體品牌 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力。抗體的特異性高,它的識別能力就強。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。